Name	Icatibant Acetate
Description	Icatibant Acetate, an antagonist of the bradykinin B2 receptor, is used in the treatment of hereditary angioedema.
In vitro	Icatibant is a decapeptide resistant to the bradykinin-degrading proteases, leading to a longer half-life than bradykinin which it antagonizes[1].
In vivo	Icatibant treatment exhibits efficacy in bradykinin-mediated angioedema attacks, and rapidly relieves symptom [1].
Storage	keep away from moisture \| Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
Solubility Information	DMSO : 100 mg/mL (73.28 mM), Sonication is recommended.
Keywords	colitis \| Bradykinin Receptor \| inhibit \| angiotensin \| HOE140 \| ulcerative \| Icatibant \| HOE-140 \| Inhibitor \| HOE 140 \| Icatibant Acetate
Inhibitors Related	Safotibant \| [Des-Arg9]-Bradykinin acetate \| B-Raf IN 14 \| Lys-Bradykinin acetate(342-10-9 free base) \| Anatibant 2HCl \| (Hyp³)-Bradykinin acetate \| MK-0686 \| ELN-441958 \| Sar-[D-Phe8]-des-Arg9-Bradykinin acetate \| 5-Hydroxy-1-methylhydantoin
Related Compound Libraries	Pain-Related Compound Library \| Bioactive Compound Library \| Membrane Protein-targeted Compound Library \| Anti-Cancer Clinical Compound Library \| Peptide Compound Library \| Drug Repurposing Compound Library \| Anti-Cancer Approved Drug Library \| Bioactive Compounds Library Max \| GPCR Compound Library \| Anti-Cancer Drug Library

Icatibant Acetate NEW

Product Introduction